Q1 Earnings Estimate for SLDB Issued By Leerink Partnrs

Key Points

• Leerink Partners forecasts Solid Biosciences' Q1 2026 EPS at ($0.46) and expects full-year earnings of ($2.84) per share.
• JPMorgan Chase & Co. and Piper Sandler have recently adjusted their price targets on Solid Biosciences, currently set at $13.00 and $17.00 respectively, maintaining an "overweight" rating.
• Solid Biosciences shares experienced a trading decline of 1.1%, with the stock currently priced at $6.11, amid fluctuating trading volumes.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2026 EPS estimates for shares of Solid Biosciences in a report issued on Wednesday, August 13th. Leerink Partnrs analyst J. Schwartz expects that the company will post earnings of ($0.46) per share for the quarter. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Solid Biosciences' Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.50) EPS and Q4 2026 earnings at ($0.48) EPS.

Several other research analysts also recently commented on the stock. Chardan Capital reaffirmed a "buy" rating and issued a $15.00 target price on shares of Solid Biosciences in a research note on Thursday, August 14th. Wall Street Zen raised shares of Solid Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday. JPMorgan Chase & Co. decreased their target price on shares of Solid Biosciences from $15.00 to $13.00 and set an "overweight" rating on the stock in a research note on Thursday, August 14th. Cantor Fitzgerald set a $16.00 target price on shares of Solid Biosciences and gave the stock an "overweight" rating in a research note on Monday, July 21st. Finally, Barclays decreased their target price on shares of Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating on the stock in a research note on Friday, May 16th. Two equities research analysts have rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $15.00.

Solid Biosciences Stock Performance

Shares of NASDAQ SLDB traded down $0.14 during mid-day trading on Friday, hitting $5.66. The stock had a trading volume of 922,643 shares, compared to its average volume of 1,922,668. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $10.37. The business has a 50 day moving average price of $5.67 and a two-hundred day moving average price of $4.48. The firm has a market cap of $440.74 million, a P/E ratio of -2.02 and a beta of 2.44.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09.

Institutional Trading of Solid Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC grew its position in shares of Solid Biosciences by 15,188.5% in the 1st quarter. CWM LLC now owns 7,950 shares of the company's stock worth $29,000 after buying an additional 7,898 shares during the period. Legal & General Group Plc grew its position in shares of Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company's stock worth $29,000 after buying an additional 4,063 shares during the period. Ameritas Investment Partners Inc. grew its position in shares of Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock worth $33,000 after buying an additional 4,534 shares during the period. Corton Capital Inc. purchased a new stake in shares of Solid Biosciences in the 4th quarter worth about $41,000. Finally, Ground Swell Capital LLC purchased a new stake in shares of Solid Biosciences in the 1st quarter worth about $42,000. 81.46% of the stock is owned by hedge funds and other institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.